Musculoskeletal Disorders

RAS Inhibitor Use May Cut Risk of MI in Rheumatoid Arthritis Patients

By December 08, 2017

The use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) was associated with a reduced risk of myocardial infarction (MI) among patients with rheumatoid arthritis (RA).

Taltz Approved for the Treatment of Active Psoriatic Arthritis

By December 04, 2017

Taltz may be administered alone or in combination with a conventional disease-modifying antirheumatic drug, such as methotrexate.

Certain Drug Classes Tied to Less Frequent Driving Impairment Warnings

By December 01, 2017

More than two-thirds (85%) of those on sedatives and narcotics reported being counseled by a provider on the possibility of impaired driving.

Osteoporosis Treatments

November 30, 2017

Osteoporosis treatment and prevention doses including recommended calcium and vitamin D supplemental doses.

Steroid Injection Site Linked to Bone Changes in Osteoarthritis Patients

By November 29, 2017

Their results found that 22-24% of the hip injection group had new osteonecrosis vs. 5-9% of the hip control group and to 5% of the shoulder injection group.

Hemophilic Arthropathy Treatment Gets Orphan Drug Designation

By November 27, 2017

TRM-201 (rofecoxib) is a highly potent COX-2 selective non-steroidal anti-inflammatory drug (NSAID) with a well-established efficacy profile.

FDA: Potentially Life-Threatening Adverse Events Linked to Limbrel

By November 22, 2017

The FDA is continuing to investigate Primus Pharmaceuticals and the manufacturing process for Limbrel, and will share updates as they become available.

Does Treating Undifferentiated Arthritis Delay RA Development?

By November 22, 2017

The primary outcome was development of rheumatoid arthritis.

Cervical Dystonia Drug Candidate Gets Orphan Drug Designation

By November 21, 2017

Treatments for cervical dystonia include oral medications, botulinum toxin injections, surgery, and complementary therapies.

Zilretta Now Available for the Management of Osteoarthritis Knee Pain

By November 20, 2017

Zilretta is the first extended-release, intra-articular injection for OA knee pain.

Enbrel Mini With AutoTouch Now Available

By November 17, 2017

The needle stays hidden during injection and a sensor can detect placement on skin. It also includes 3 difference injection speeds, a progress bar and a speaker.

New Drug-Free Therapy Available for Arthritis Pain

By November 16, 2017

The device has 14 pre-set therapy modes designed to block acute or chronic pain or to imitate exercise recovery, endurance and muscle strength.

FDA: Gout Drug Linked to Increased Risk of Heart-Related Death

By November 15, 2017

The FDA required the Uloric drug manufacturer, Takeda Pharmaceuticals, to conduct this safety study when the medicine was approved in 2009.

Does Inhaled Corticosteroid Use Up the Risk of Fracture in Children?

November 14, 2017

Inhaled corticosteroids are not associated with increased odds of fracture in the pediatric asthma population

Anti-Inflammatory Foods May Help With RA Symptoms, Progression

By November 08, 2017

Specific foods that were highlighted include dried plums, blueberries, pomegranates, whole grains, ginger, turmeric, specific oils, and teas; these foods were found to reduce inflammatory cytokines, joint stiffness, pain, and oxidative stress.

Exercise Intensity and Mortality Risk: What's the Link?

November 08, 2017

A significant inverse correlation was seen in age- and wear time-adjusted analysis for LPA, but this correlation was no longer apparent after adjustment for potential confounders and MVPA.

USPSTF Issues Recommendations for Osteoporosis Screening

November 08, 2017

Screening for osteoporosis with bone measurement testing should also occur in postmenopausal women <65 years who are at increased risk of osteoporosis as determined by a formal clinical risk assessment tool (B recommendation).

Factors Associated With Successful Biologics Tapering in RA

November 07, 2017

There were also significant differences between the groups in concomitant oral corticosteroid use (43.1 vs. 34.8% in the stable treatment and DT groups, respectively) and CRP level (1.9±2.5 vs. 1.1±1.3 respectively).

Muscle Spasm Treatments

October 30, 2017

Muscle spasm treatment chart with dosing regimens for muscle relaxants and other medications.

Arthritis Treatments: DMARDS and Other Immune Modulators

October 30, 2017

A comparative list of treatment options for arthritis including DMARDS and other immune modulators.

Disease-Modifying Osteoarthritis Tx Granted Fast Track Status

By October 25, 2017

There are currently no DMOADs approved for use in OA. MIV-711 is a selective inhibitor of cathepsin K, which is the principal protease involved in breaking down collagen in bones and cartilage.

Does Drinking Water Before Vaccination Prevent Postvaccination Presyncope?

October 24, 2017

In multivariable analysis, presyncope was correlated with younger age, history of passing out or nearly passing out after an injection or blood draw, anxiety before vaccination, receiving more than one injected vaccine, and greater post-vaccination pain.

Tofacitinib Efficacy Investigated in Patients With Psoriatic Arthritis

October 20, 2017

Tofacitinib is superior for patients with inadequate response to TNF inhibitors or conventional DMARDs

Discontinuation Rates Examined After Switch to Biosimilar

By October 18, 2017

Study authors aimed to assess the pharmacokinetics, efficacy, immunogenicity, safety, and drug discontinuation after switching from infliximab (Remicade) to the biosimilar CT-P13 in 192 patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis in daily practice.

Stelara Approved to Treat Adolescent Patients With Plaque Psoriasis

By October 16, 2017

The expanded approval was supported by data from a Phase 3 study that evaluated the safety and efficacy of subcutaneous Stelara in adolescents aged ≥12 years.

Has Mass Media Criteria for What Constitutes Beauty Evolved?

October 12, 2017

In 1990, Fitzpatrick skin types I to III represented 88% of the celebrities on the list and Fitzpatrick skin types IV to VI represented 12%; in contrast, in 2017, Fitzpatrick skin types I to III and IV to VI represented 70.4 and 29.6%, respectively

Duzallo Now Available for the Treatment of Uncontrolled Gout

By October 10, 2017

The fixed-dose product combines lesinurad, a uric acid transporter 1 (URAT1) inhibitor, with allopurinol, a xanthine oxidase inhibitor in one tablet.

Zilretta Approved to Treat Osteoarthritis Knee Pain

By October 10, 2017

Phase 3 results found that Zilretta achieved statistically significant reductions on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) sections for pain, stiffness and function compared to immediate-release TCA.

CombiPatch, Minivelle Patches No Longer in Shortage

By October 03, 2017

Noven announced that CombiPatch (estradiol/norethindrone acetate transdermal system) and Minivelle (estradiol transdermal system) are now readily available following a temporary product shortage.

Uloric Dosing Updated to Include Patients with Severe Renal Impairment

By September 27, 2017

The new labeling now recommends patients with severe renal impairment be limited to a dose of 40mg once daily.